Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:43:56 EST Sat 13 Dec 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:FEMY - FEMASYS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FEMY - Q1.00.8455·0.87960.80.8567+0.00160.2761.95909330.8551  0.89  0.8451.80  0.306719:56:16Nov 1415 min RT 2¢

Recent Trades - Last 10 of 933
Time ETExPriceChangeVolume
19:56:16Q0.85670.00161,020
19:45:46Q0.870.01493,000
19:38:56Q0.860.00491
19:16:51Q0.8570.0019100
19:13:17Q0.870.014990
17:16:33Q0.860.00491,000
17:14:20Q0.85680.0017300
17:04:42Q0.860.00491
16:40:12Q0.860.0049100
16:40:07Q0.860.004910

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-14 16:01U:FEMYNews ReleaseFemasys Announces Third Quarter Financial Results for 2025
2025-11-10 09:00U:FEMYNews ReleaseFemasys Advances Global Growth with Second Partner Order for FemBloc(TM) in Europe
2025-11-03 08:30U:FEMYNews ReleaseFemasys Secures FDA Approval to Advance Final FemBloc(TM) Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
2025-10-22 09:00U:FEMYNews ReleaseFemasys Announces Initiation of Post-Market Surveillance Study for FemBloc(TM) Permanent Birth Control in Europe
2025-10-16 09:00U:FEMYNews ReleaseFemasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
2025-09-25 09:00U:FEMYNews ReleaseFemasys Accelerates European Growth for FemBloc(TM) with Kebomed Partnership
2025-09-22 09:00U:FEMYNews ReleaseFemasys Partners with Medical Electronic Systems to Launch FemSperm(TM) Analysis Kit for use with FemaSeed
2025-09-11 09:00U:FEMYNews ReleaseFemasys Expands FemSperm(TM) Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed(TM)
2025-09-08 09:00U:FEMYNews ReleaseFemasys Secures Regulatory Approval for FemBloc(TM) Permanent Birth Control in New Zealand
2025-09-02 09:00U:FEMYNews ReleaseFemasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
2025-08-25 23:44U:FEMYNews ReleaseFemasys Announces Pricing of $8.0 Million Underwritten Public Offering
2025-08-21 09:00U:FEMYNews ReleaseFemasys Announces FemSperm(TM) Kit to Activate Gynecologists and Advance FemaSeed(TM) Fertility Platform
2025-08-20 09:00U:FEMYNews ReleaseFemasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
2025-08-08 16:05U:FEMYNews ReleaseFemasys Announces Second Quarter Financial Results for 2025
2025-08-06 09:00U:FEMYNews ReleaseFemasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
2025-07-01 09:00U:FEMYNews ReleaseFemasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed(TM) for First-Line Infertility Treatment and FemVue Diagnostic
2025-06-25 09:00U:FEMYNews ReleaseFemasys Announces Historic Milestone with European Approval of FemBloc(TM), the First Non-Surgical Permanent Birth Control
2025-06-17 09:00U:FEMYNews ReleaseFemasys Names New Chief Commercial Officer to Drive Execution and Global Growth
2025-06-11 09:00U:FEMYNews ReleaseFemasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed(TM) in its More than 8 Locations
2025-05-30 08:00U:FEMYNews ReleaseFemasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million